Accessibility Menu
Illumina logo

Illumina(NASDAQ) ILMN

Market Cap$29.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+913%
5 Year-62%
1 Year+98%
1 Month+2%
$192.91
+0.04%
+0.07Today
After hours$192.87-$0.04 (-0.02%)
Illumina last closing stock price
MetricPriceDate
Last closeUSD 192.912026-08-12
Illumina stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.48%USD 199.872026-08-05
1 month+1.5%USD 190.052026-07-13
3 month+34.68%USD 143.242026-05-14
Year to date+47.08%USD 131.162025-12-31
1 year+98.1%USD 97.382025-08-12
3 year+9.71%USD 175.842023-08-11
5 year-61.73%USD 504.022021-08-13
Since inception+913.12%USD 19.032000-07-28

Illumina Financials at a Glance

Market Cap

$29.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.49B

Net Income (TTM)

$825.00M

EPS (TTM)

$5.37

P/E Ratio

35.95

Dividend

$0.00

Beta (Volatility)

1.24 (Average)

Price

$192.91

Volume

155.999

Open

$192.01

Previous Close

$192.91

Daily Range

$189.24 - $193.55

52-Week Range

$88.00 - $207.00

Estimated Earnings Date

Oct 29, 2026

ILMN News

Medical-gloved hand holding human DNA in front of sequence imaging.jpg

4 Best Genetic Sequencing Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026
Two scientists looking at a monitor showing brain scans.

Best Cancer Stocks for 2026 and How to Invest

Keith SpeightsMay 19, 2026
Doctor holding clipboard stands with virtual DNA double helix in the air near him.

Best Genomics Stocks for 2026 and How to Invest

Lyle DalyApr 18, 2026
Foolcom-Featured.png

Illumina (ILMN) Q2 EPS Jumps 9%

Motley Fool Markets TeamAug 1, 2025
Copy of TMF YT Thumbnails - 2025-07-24T062931.074

Illumina: A 5.2 Rating Amid Challenges and Opportunities

Motley Fool YouTubeJul 31, 2025
Person in a lab gazing into a microscope

Why Illumina Stock Got Mashed on Monday

Eric VolkmanFeb 10, 2025
Illumina_Stock_Drop_Q4_Earnings_2025

Why Illumina Stock Is Sinking Today

Johnny RiceFeb 7, 2025
Two people in white lab coats looking at a computer display

Why Illumina Stock Plummeted Today

Eric VolkmanFeb 4, 2025
Page 1

ILMN: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Illumina

Illumina makes machines and chemicals that read genetic code. These tools help doctors and scientists find diseases and study living things. Hospitals and labs use this technology to provide better care for patients.

What Illumina Sells

  • Sequencing Consumables: Reagents, flow cells, and library kits used to run genetic tests; accounted for 74% of revenue in 2025.
  • Sequencing Instruments: High-tech machines like the NovaSeq X Plus that read DNA for researchers; represented 11% of revenue in 2025.
  • Array Solutions: Tools used to detect millions of known genetic markers in a single study; made up 8% of revenue in 2025.
  • Informatics Tools: Software platforms like BaseSpace and DRAGEN that help labs process and analyze large amounts of data.
  • Professional Services: Whole-genome sequencing and maintenance contracts for customers; comprised 15% of revenue in 2025.

Recent Business Moves

  • Completed the spin-off of GRAIL in June 2024 to return it to an independent public company.
  • Acquired SomaLogic to expand into the proteomics market, which involves studying the proteins in a cell.
  • Purchased certain assets from Standard BioTools to strengthen the company's technology portfolio.
  • Launched the MiSeq i100 series in 2024 to provide faster and simpler benchtop sequencing for smaller labs.

The Competitive Edge

Illumina maintains a global distribution network that reached customers in over 140 countries in 2025. The company uses its extensive patent library and specialized manufacturing in the U.S., U.K., and Singapore to maintain high technical standards.

The Scorecard

  • Revenue reached $1.2 billion in Q4 2025, a 5% increase compared to the previous year.
  • Net income rose to $334 million in Q4 2025, up 78.6% from the same period in 2024.
  • Operating income grew 26.7% year-over-year to $256 million in Q4 2025.
  • Free cash flow was $267 million in Q4 2025, down 20.3% from the prior year.
  • Research and development spending was $967 million for the full year 2025.

Bottom Line

Illumina has transitioned from a research-focused startup to a global provider of clinical diagnostic tools. By separating from non-core assets and focusing on high-speed sequencing, the company continues to center its business on the growing genomics market.

AI Generated • Apr 20, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

8,600

CEO

Jacob Thaysen, PhD

Website

www.illumina.com

Headquarters

San Diego, CA 92122, US

ILMN Financials

Key Financial Metrics (TTM)

Gross Margin

66.79%

Operating Margin

20.97%

Net Income Margin

18.36%

Return on Equity

31.08%

Return on Capital

16.38%

Return on Assets

12.41%

Earnings Yield

2.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$29.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

151.00M

Volume

155.999

Avg. Volume

1.97M

Financials (TTM)

Gross Profit

$3.00B

Operating Income

$942.00M

EBITDA

$1.36B

Operating Cash Flow

$1.10B

Capital Expenditure

-$156.00M

Free Cash Flow

$939.00M

Cash & ST Invst.

$1.17B

Total Debt

$2.53B

Illumina Performance Analysis

Illumina annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,584,000,0001.3%
20232023-12-31USD 4,504,000,000-1.7%
20242024-12-31USD 4,357,000,000-3.3%
20252025-12-31USD 4,338,000,000-0.4%
Illumina sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-282.5%
Q42025-12-287.1%
Q12026-03-29-5.9%
Q22026-06-286.2%
Illumina annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -28.05N/A
20232023-12-31USD -7.35-73.8%
20242024-12-31USD -7.694.7%
20252025-12-31USD 5.45N/A
Illumina sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-35.3%
Q42025-12-28123.7%
Q12026-03-29-59.9%
Q22026-06-2855.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.16B

+9.6%

Gross Profit

$770.00M

+7.4%

Gross Margin

66.44%

N/A

Market Cap

$29.13BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.39M

N/A

Employees

8,600

N/A

Net Income

$207.00M

-11.9%

EBITDA

$330.00M

-17.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.17B

+1.1%

Total Debt

$2.53B

-2.7%

Accounts Receivable

$764.00M

+6.7%

Inventory

$629.00M

+9.4%

Long Term Debt

$1.95B

-3.7%

Short Term Debt

$582.00M

+0.7%

Return on Assets

12.41%

N/A

Return on Invested Capital

18.57%

N/A

Free Cash Flow

$161.00M

-23.7%

Operating Cash Flow

$201.00M

-14.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WATWaters Corporation
$416.15+0.28%
LHLabcorp Holdings Inc.
$323.48+0.33%
DGXQuest Diagnostics Incorporated
$237.77+0.11%
WSTWest Pharmaceutical Services, Inc.
$352.29+0.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$9.77+0.00%
NOKNokia
$10.32+0.09%
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%

Questions About ILMN

What is the current price of Illumina?

Illumina is trading at $192.91 per share.

What is the 52-week range for Illumina?

Over the past 52 weeks, Illumina has traded between $88.00 and $207.00.

How much debt does Illumina have?

As of the most recent reporting period, Illumina reported total debt of $2.53B.

How much cash does Illumina have on hand?

Illumina reported $1.04B in cash and cash equivalents in its most recent financial results.

What is Illumina’s dividend yield?

Illumina does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services